NeuroSense Therapeutics Ltd. Price & Performance (NRSNW)

NeuroSense Therapeutics is preparing for a pivotal Phase 3 trial of PrimeC, after Phase 2b data showed a 33% reduction in ALS progression and 58% improved survival. The company is also seeking early Canadian access, with potential annual revenues of $100–150 million, and continues partnership talks with a major pharmaceutical firm.123

Ongoing negotiations with a global pharmaceutical partner could provide NeuroSense with critical funding for its Phase 3 ALS trial. The company’s regulatory strategy includes aligning with FDA guidance and pursuing expedited Canadian approval, aiming to accelerate PrimeC’s path to market and boost future revenue opportunities.43

PrimeC’s Phase 2b trial success positions NeuroSense as a leader in ALS innovation, but its $3.4 million cash reserves highlight the need for additional funding. Cost reductions and strong efficacy data have improved outlook, yet securing a partnership remains essential for advancing to Phase 3 and ensuring long-term viability.53